Ishara Investments LP Purchases Shares of 10,000 Insmed, Inc. $INSM

Ishara Investments LP purchased a new stake in Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,740,000. Insmed accounts for approximately 2.0% of Ishara Investments LP’s portfolio, making the stock its 18th biggest holding.

Other hedge funds have also recently bought and sold shares of the company. CIBC Private Wealth Group LLC boosted its stake in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares during the period. Kingsview Wealth Management LLC boosted its stake in shares of Insmed by 2.7% during the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 60 shares during the period. Choreo LLC boosted its stake in shares of Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 65 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 69 shares during the period. Finally, ORG Partners LLC boosted its stake in shares of Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 74 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have recently commented on INSM shares. Raymond James Financial started coverage on Insmed in a research note on Friday, April 10th. They set an “outperform” rating and a $200.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Leerink Partners lifted their target price on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 24th. Guggenheim reduced their target price on Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Truist Financial reduced their target price on Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $211.86.

Insider Transactions at Insmed

In related news, CFO Sara Bonstein sold 2,404 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the sale, the chief financial officer directly owned 69,082 shares in the company, valued at $7,065,016.14. The trade was a 3.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 7,605 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $777,763.35. Following the completion of the sale, the chief executive officer owned 265,432 shares of the company’s stock, valued at $27,145,730.64. This trade represents a 2.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 149,783 shares of company stock valued at $22,902,672. Company insiders own 2.10% of the company’s stock.

Insmed Stock Performance

INSM opened at $98.45 on Thursday. The business has a fifty day simple moving average of $120.61 and a 200 day simple moving average of $148.61. The company has a market capitalization of $21.34 billion, a PE ratio of -17.12 and a beta of 0.79. Insmed, Inc. has a 1 year low of $90.39 and a 1 year high of $212.75. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. The business had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm’s quarterly revenue was up 229.7% on a year-over-year basis. During the same period in the previous year, the company posted ($1.42) EPS. Research analysts expect that Insmed, Inc. will post -2.54 EPS for the current year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.